Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of ...

Unicycive, which was seeking approval of oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease on dialysis, said the FDA issued a so-called complete response letter ...

The FDA has awarded the fast-track designation for the CKD indication based on that result, as well as the promise of an ongoing trial – EMPA-KIDNEY – which is looking at kidney disease ...

Unicycive had submitted the New Drug Application for OLC to treat hyperphosphatemia in patients with chronic kidney disease on dialysis. The company emphasized that the FDA has not highlighted any ...

Bhatt was just 26 when she was diagnosed with polycystic kidney disease (PKD)—a condition she discovered by chance while ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the. On June 4, the company published pre-specified analyses for its ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

ProKidney Corp. (Nasdaq: PROK) ('ProKidney” or the 'Company'), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the completion of ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Autosomal dominant tubulointerstitial kidney disease, better known as ADTKD, is a group of kidney disorders which are inherited. Sheri and David Dafoe have first-hand knowledge ...